VIAL CLARO, PABLO AGUSTIN
Thumbnail Image
Preferred name
VIAL CLARO, PABLO AGUSTIN
Main Affiliation
Email
pvial@udd.cl
ORCID
Scopus Author ID
17339613100

Research Output

2024 2024 2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 0 0 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8

Filters

1 1 1
59
Reset filters

Settings
Now showing 1 - 10 of 59
No Thumbnail Available
Publication

Hantavirosis: Clinical and epidemiological characteristics of pediatric patients in Chile

2010 , Marcela Ferrés G , Carmen Sandoval C , DELGADO BECERRA, OROZIMBA IRIS , Viviana Sotomayor P , OLEA NORMANDIN, ANDREA MARIA , VIAL CLARO, PABLO AGUSTIN

View
No Thumbnail Available
Publication

Overcoming Health Inequities: Spatial Analysis of Seroprevalence and Vaccination Against COVID-19 in Chile

2024 , Muriel Ramírez-Santana , Juan Correa , Loreto Núñez Franz , APABLAZA SALINAS, MAURICIO IVÁN , RUBILAR RAMIREZ, PAOLA ANDREA , VIAL COX, MARIA CECILIA , CORTES SALINAS, LINA JIMENA , HORMAZABAL CASTILLO, JUAN PATRICIO , Luis Canales , VIAL CLARO, PABLO AGUSTIN , AGUILERA SANHUEZA, XIMENA PAZ

View
No Thumbnail Available
Publication

Incubation period of hantavirus cardiopulmonary syndrome

2006-01-01 , VIAL CLARO, PABLO AGUSTIN , Valdivieso, Francisca , Mertz, Gregory , Castillo, Constanza , Belmar, Edith , DELGADO BECERRA, OROZIMBA IRIS , Tapia, Mauricio , Ferrés, Marcela

The potential incubation period from exposure to onset of symptoms was 7-39 days (median 18 days) in 20 patients with a defined period of exposure to Andes virus in a high-risk area. This period was 14-32 days (median 18 days) in 11 patients with exposure for ≤48 hours.

View
No Thumbnail Available
Publication

Etiología viral en la neumonía del adulto adquirida en la comunidad en un hospital del sur de Chile

2012 , M. Luisa Rioseco Z , Raúl Riquelme O , Mauricio Riquelme O , Carlos Inzunza P , Paola Oyarzún G , Yasna Agüero O , Marcela Ferrés G , VIAL CLARO, PABLO AGUSTIN , Rodrigo Fasce P , Antoni Torres M

View
No Thumbnail Available
Publication

Zika virus in a New World [Virus Zika en un nuevo mundo]

2016 , Pablo Agustín Vial Claro , ARAOS BRALIC, RAFAEL IGNACIO

View
No Thumbnail Available
Publication

Addition of an arterio-venous shunt during veno-arterial extracorporeal life support in a patient with Hantavirus pulmonary syndrome

2005-11-21 , Tomicic F, Vinko , Espinoza R, Mauricio , Torres M, Javier , Abarca Z, Juan , Montes S, José Miguel , Luppi N, Mario , Concha F, Andrés , Reynolds H, Enrique , Laporte M, Alberto , Canals L, Claudio , VIAL CLARO, PABLO AGUSTIN

A subgroup of patients infected with the Hantavirus develops a pulmonary syndrome (HPS) characterized by severe acute respiratory failure and myocardial depression, that has a high mortality rate. Extracorporeal life support (ECLS) could be a valuable therapeutic tool in such patients. We report a 24 years old male with HPS that was successfully managed when an arterio-venous shunt was added to a conventional veno-arterial ECLS technique. Precise criteria have been developed to predict which patients should be considered for this treatment.

View
No Thumbnail Available
Product

Clinical trial data - An international, interlaboratory ring trial confirms the feasibility of an extraction-less “direct” RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples

2022 , VIAL CLARO, PABLO AGUSTIN , VIAL COX, MARIA CECILIA

View
No Thumbnail Available
Publication

Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study

2023 , HORMAZABAL CASTILLO, JUAN PATRICIO , Loreto Nuñez-Franz , RUBILAR RAMIREZ, PAOLA ANDREA , APABLAZA SALINAS, MAURICIO IVÁN , VIAL COX, MARIA CECILIA , CORTES SALINAS, LINA JIMENA , Macarena Said , Kathya Olivares , VIAL CLARO, PABLO AGUSTIN , Muriel Ramírez-Santana , GONZALEZ WIEDMAIER, CLAUDIA MARTA , Natalia González , AGUILERA SANHUEZA, XIMENA PAZ

View
No Thumbnail Available
Publication

Serological assays for the detection of human Andes hantavirus infections based on its yeast-expressed nucleocapsid protein

2006-01-01 , Schmidt, Jonas , Meisel, Helga , Capria, Silvana G. , Petraityte, Rasa , Lundkvist, Åke , Hjelle, Brian , VIAL CLARO, PABLO AGUSTIN , Padula, Paula , Krüger, Detlev H. , Ulrich, Rainer

Background: The objective of the study was to develop and evaluate IgM and IgG ELISAs and an IgG Western blottest for the serological detection of human infections with Andes virus (ANDV), the major cause of hantavirus cardiopulmonary syndrome (HCPS) in South America. Methods: The entire nucleocapsid (N) protein-encoding sequence of ANDV (strain AH-1) was cloned and expressed in the yeast Saccharomyces cerevisiae. The polyhistidine-tagged recombinant N (rN) protein of ANDV was purified by nickel-chelation chromatography and characterized by its reactivity with different N-specific monoclonal antibodies. To detect an antibody response directed against ANDV in humans, indirect IgM and IgG ELISAs and an IgG Western blot test based on ANDV rN antigen were developed. The evaluation of the tests was performed using a negative serum panel and 63 blinded sera from Argentina and Chile, containing acute-phase and convalescent sera from HCPS patients. Results: The specificities and sensitivities for the IgM and IgG ELISAs were demonstrated to be very high. The IgG ELISA data were confirmed by the IgG Western blot assay based on the same rN antigen. Almost all anti-ANDV-positive sera reacted to higher endpoint titers with N protein of ANDV than with those of Sin Nombre, Laguna Negra or Puumala virus. The cross-reactivity of anti-ANDV-N IgG-positive sera to rN proteins of other hantaviruses was found to be increased with time after the onset of HCPS. Conclusion: The high sensitivity of the novel assays should facilitate early diagnosis of ANDV infections and might contribute to a successful treatment of HCPS patients. Copyright © 2006 S. Karger AG.

View
No Thumbnail Available
Publication

SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

2022 , AGUILERA SANHUEZA, XIMENA PAZ , HORMAZABAL CASTILLO, JUAN PATRICIO , VIAL COX, MARIA CECILIA , CORTES SALINAS, LINA JIMENA , GONZALEZ WIEDMAIER, CLAUDIA MARTA , RUBILAR RAMIREZ, PAOLA , APABLAZA SALINAS, MAURICIO IVÁN , Muriel Ramírez-Santana , Gloria Icaza , Loreto Nuñez-Franz , Rubén Quezada-Gate , Macarena Said , PEREZ ACUÑA, CLAUDIA VERONICA , CASTILLO LABORDE, CARLA CECILIA , Carolina Sacristán Ramírez , VIAL CLARO, PABLO AGUSTIN

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

View